Umoja Biopharma Entered into a Research Collaboration with IASO Biotherapeutics to Develop Off-the-Shelf Therapies for Hematological Malignancies
- The collaboration will combine Umoja’s iCIL platform & IASO’s chimeric Ag receptors to develop off-the-shelf therapies for hematological malignancies with an increasing patient accessibility
- For the differentiation & expansion of iCILs, a novel class of innate lymphocytes with potent anti-tumor activity, Umoja's iPSC-based allogeneic cell therapy platform uses its ShRED manufacturing process
- IASO aims to make its innovative therapies available to a larger global population by using its strong capabilities in screening CARs through its fully-human Ab discovery platform (IMARS). IASO also has an in-house GMP facility for plasmid, virus vector & CAR-T cell manufacturing with a ~90% success rate
Ref: Globenewswire | Image: IASO Biotherapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.